Last 12 months
Inside the activity.
0 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 9 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 9, 2026 22:28 UTC |
Schayowitz AdamEVP, Head of R&D
|
Exercise / conversionRestricted Stock Unit · Derivative | 37,037 | $0.00 | $0.00 |
DisclosureSEC source: 0002127119-26-000006 · wk-form4_1791584905.xml · derivative · entry 3 Schayowitz Adam · CIK 0002127119 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,074 Underlying: Common Stock · 37,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F5 · derivative.exercise_date: Restricted stock units ("RSUs") granted October 9, 2025; vest in three equal annual installments beginning October 9, 2026. F5 · derivative.expiration_date: Restricted stock units ("RSUs") granted October 9, 2025; vest in three equal annual installments beginning October 9, 2026. Read SEC document |
| October 09, 2026 Filed Oct 9, 2026 22:28 UTC |
Schayowitz AdamEVP, Head of R&D
|
SaleCommon Stock | 13,832 | $25.85 | $357,557.20 |
DisclosureSEC source: 0002127119-26-000006 · wk-form4_1791584905.xml · nonDerivative · entry 2 Schayowitz Adam · CIK 0002127119 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,205 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.85 to $25.88, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 09, 2026 Filed Oct 9, 2026 22:28 UTC |
Schayowitz AdamEVP, Head of R&D
|
Exercise / conversionCommon Stock | 37,037 | $0.00 | $0.00 |
DisclosureSEC source: 0002127119-26-000006 · wk-form4_1791584905.xml · nonDerivative · entry 1 Schayowitz Adam · CIK 0002127119 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on October 9, 2025. Read SEC document |
| July 06, 2026 Filed Jul 6, 2026 21:29 UTC |
Hollywood MarkEVP & Chief Operating Officer
|
GrantCommon Stock | 939 | $22.22 | $20,864.58 |
DisclosureSEC source: 0002104446-26-000009 · wk-form4_1783373362.xml · nonDerivative · entry 1 Hollywood Mark · CIK 0002104446 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,852 F1 · kind: The shares were acquired under the Issuer's Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of January 1, 2026 to June 30, 2026. F2 · price: The purchase price reflects a 15% discount to the closing price of the Issuer's Common Stock on June 30, 2026 pursuant to the provisions of the ESPP. Read SEC document |
| May 13, 2026 Filed May 15, 2026 21:00 UTC |
Schneider Paul REVP, General Counsel
|
GrantRestricted Stock Unit · Derivative | 119,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-227140 · ownership.xml · derivative · entry 2 Schneider Paul R · CIK 0001455484 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 119,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F3 · derivative.exercise_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. F3 · derivative.expiration_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. Read SEC document |
| May 13, 2026 Filed May 15, 2026 21:00 UTC |
Schneider Paul REVP, General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 178,000 | $0.00 Strike: $24.57 | $0.00 |
DisclosureSEC source: 0001193125-26-227140 · ownership.xml · derivative · entry 1 Schneider Paul R · CIK 0001455484 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,000 Underlying: Common Stock · 178,000 shares Expires 2036-05-12 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:10 UTC |
Platshon ScottEVP, Chief Business Officer
|
GrantPerformance Stock Unit · Derivative | 76,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-151264 · ownership.xml · derivative · entry 3 Platshon Scott · CIK 0001816539 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 76,000 shares Expires not disclosed F4 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. F5 · derivative.exercise_price: (Continued from footnote 4) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F4 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. F5 · derivative.exercise_date: (Continued from footnote 4) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F4 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. F5 · derivative.expiration_date: (Continued from footnote 4) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:10 UTC |
Platshon ScottEVP, Chief Business Officer
|
GrantRestricted Stock Unit · Derivative | 47,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-151264 · ownership.xml · derivative · entry 2 Platshon Scott · CIK 0001816539 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F3 · derivative.exercise_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. F3 · derivative.expiration_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:10 UTC |
Platshon ScottEVP, Chief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001193125-26-151264 · ownership.xml · derivative · entry 1 Platshon Scott · CIK 0001816539 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-04-08 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:10 UTC |
Schayowitz AdamSee Remarks
|
GrantPerformance Stock Unit · Derivative | 76,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-151265 · ownership.xml · derivative · entry 3 Schayowitz Adam · CIK 0002127119 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 76,000 shares Expires not disclosed F4 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. F5 · derivative.exercise_price: (Continued from footnote 1) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F4 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. F5 · derivative.exercise_date: (Continued from footnote 1) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F4 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. F5 · derivative.expiration_date: (Continued from footnote 1) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:10 UTC |
Schayowitz AdamSee Remarks
|
GrantRestricted Stock Unit · Derivative | 47,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-151265 · ownership.xml · derivative · entry 2 Schayowitz Adam · CIK 0002127119 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F3 · derivative.exercise_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. F3 · derivative.expiration_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:10 UTC |
Schayowitz AdamSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001193125-26-151265 · ownership.xml · derivative · entry 1 Schayowitz Adam · CIK 0002127119 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-04-08 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 18:24 UTC |
Stafford KristinEVP, Chief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-145305 · ownership.xml · derivative · entry 3 Stafford Kristin · CIK 0001970438 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F4 · derivative.exercise_date: RSUs vest in three equal annual installments beginning on first anniversary of grant date. F4 · derivative.expiration_date: RSUs vest in three equal annual installments beginning on first anniversary of grant date. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 18:24 UTC |
Stafford KristinEVP, Chief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 119,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-145305 · ownership.xml · derivative · entry 2 Stafford Kristin · CIK 0001970438 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 119,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F3 · derivative.exercise_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. F3 · derivative.expiration_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 18:24 UTC |
Stafford KristinEVP, Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 178,000 | $0.00 Strike: $25.84 | $0.00 |
DisclosureSEC source: 0001193125-26-145305 · ownership.xml · derivative · entry 1 Stafford Kristin · CIK 0001970438 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,000 Underlying: Common Stock · 178,000 shares Expires 2036-04-05 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:59 UTC |
Ciongoli Gregory AustinDirector
|
GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010864 · ownership.xml · derivative · entry 2 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:59 UTC |
Ciongoli Gregory AustinDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010864 · ownership.xml · derivative · entry 1 Ciongoli Gregory Austin · CIK 0002023732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:42 UTC |
Mahony SusanDirector
|
GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010843 · ownership.xml · derivative · entry 2 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:42 UTC |
Mahony SusanDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010843 · ownership.xml · derivative · entry 1 Mahony Susan · CIK 0001463321 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 20:56 UTC |
Neu KelvinDirector
|
GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010860 · ownership.xml · derivative · entry 2 Neu Kelvin · CIK 0001554699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 20:56 UTC |
Neu KelvinDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010860 · ownership.xml · derivative · entry 1 Neu Kelvin · CIK 0001554699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC |
Galbraith KennethDirector · Chair & CEO
|
GrantPerformance Stock Unit · Derivative | 222,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · derivative · entry 6 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,000 Underlying: Common Stock · 222,000 shares Expires not disclosed F8 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 111,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the reporting person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.exercise_price: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F8 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 111,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the reporting person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.exercise_date: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F8 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 111,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the reporting person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.expiration_date: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC |
Galbraith KennethDirector · Chair & CEO
|
GrantRestricted Stock Unit · Derivative | 144,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · derivative · entry 5 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F7 · derivative.exercise_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. F7 · derivative.expiration_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC |
Galbraith KennethDirector · Chair & CEO
|
GrantStock Option (Right to Buy) · Derivative | 216,000 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · derivative · entry 4 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,000 Underlying: Common Stock · 216,000 shares Expires 2036-01-11 F6 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC |
Galbraith KennethDirector · Chair & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 64,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · derivative · entry 3 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Stock · 64,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F5 · derivative.exercise_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. F5 · derivative.expiration_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC |
Galbraith KennethDirector · Chair & CEO
|
SaleCommon Stock | 30,424 | $22.67 | $689,818.56 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · nonDerivative · entry 2 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,842 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 19:07 UTC |
Galbraith KennethDirector · Chair & CEO
|
Exercise / conversionCommon Stock | 64,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010790 · ownership.xml · nonDerivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:56 UTC |
Landry Robert EDirector
|
GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010859 · ownership.xml · derivative · entry 2 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:56 UTC |
Landry Robert EDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010859 · ownership.xml · derivative · entry 1 Landry Robert E · CIK 0001585160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 21:00 UTC |
Smith Jeffrey T LEVP & Chief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 17,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010865 · ownership.xml · derivative · entry 3 Smith Jeffrey T L · CIK 0001604800 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,334 Underlying: Common Stock · 17,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. F5 · derivative.expiration_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 21:00 UTC |
Smith Jeffrey T LEVP & Chief Medical Officer
|
SaleCommon Stock | 9,310 | $22.67 | $211,090.29 |
DisclosureSEC source: 0001193125-26-010865 · ownership.xml · nonDerivative · entry 2 Smith Jeffrey T L · CIK 0001604800 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,708 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 21:00 UTC |
Smith Jeffrey T LEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 17,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010865 · ownership.xml · nonDerivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 20:50 UTC |
Campoy CarlosDirector
|
GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010852 · ownership.xml · derivative · entry 2 Campoy Carlos · CIK 0001761518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 20:50 UTC |
Campoy CarlosDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010852 · ownership.xml · derivative · entry 1 Campoy Carlos · CIK 0001761518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:54 UTC |
Cesano AlessandraDirector
|
GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010856 · ownership.xml · derivative · entry 2 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:54 UTC |
Cesano AlessandraDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010856 · ownership.xml · derivative · entry 1 Cesano Alessandra · CIK 0001827015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC |
Moore Paul AndrewChief Scientific Officer
|
GrantPerformance Stock Unit · Derivative | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · derivative · entry 6 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires not disclosed F8 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.exercise_price: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F8 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.exercise_date: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F8 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.expiration_date: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC |
Moore Paul AndrewChief Scientific Officer
|
GrantRestricted Stock Unit · Derivative | 47,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · derivative · entry 5 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. F7 · derivative.expiration_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC |
Moore Paul AndrewChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · derivative · entry 4 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-01-11 F6 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC |
Moore Paul AndrewChief Scientific Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 17,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · derivative · entry 3 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,334 Underlying: Common Stock · 17,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. F5 · derivative.expiration_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC |
Moore Paul AndrewChief Scientific Officer
|
SaleCommon Stock | 9,560 | $22.67 | $216,758.66 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · nonDerivative · entry 2 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,497 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC |
Moore Paul AndrewChief Scientific Officer
|
Exercise / conversionCommon Stock | 17,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · nonDerivative · entry 1 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:30 UTC |
Cherry Brian NDirector
|
GrantRestricted Stock Unit · Derivative | 15,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-011793 · ownership.xml · derivative · entry 2 Cherry Brian N · CIK 0001290922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,400 Underlying: Common Stock · 15,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest in three equal annual installments beginning on first anniversary of grant date. F3 · derivative.expiration_date: RSUs vest in three equal annual installments beginning on first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:30 UTC |
Cherry Brian NDirector
|
GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-011793 · ownership.xml · derivative · entry 1 Cherry Brian N · CIK 0001290922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest in 36 equal monthly installments starting one month after grant date of January 12, 2026. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:11 UTC |
Hollywood MarkEVP & Chief Operating Officer
|
GrantPerformance Stock Unit · Derivative | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-011885 · ownership.xml · derivative · entry 6 Hollywood Mark · CIK 0002104446 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires not disclosed F8 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. F9 · derivative.exercise_price: (Continued from footnote 8) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F8 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. F9 · derivative.exercise_date: (Continued from footnote 8) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F8 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. F9 · derivative.expiration_date: (Continued from footnote 8) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:11 UTC |
Hollywood MarkEVP & Chief Operating Officer
|
GrantRestricted Stock Unit · Derivative | 47,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-011885 · ownership.xml · derivative · entry 5 Hollywood Mark · CIK 0002104446 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. F7 · derivative.expiration_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:11 UTC |
Hollywood MarkEVP & Chief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-011885 · ownership.xml · derivative · entry 4 Hollywood Mark · CIK 0002104446 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-01-11 F6 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:11 UTC |
Hollywood MarkEVP & Chief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 17,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-011885 · ownership.xml · derivative · entry 3 Hollywood Mark · CIK 0002104446 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,334 Underlying: Common Stock · 17,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. F5 · derivative.expiration_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:11 UTC |
Hollywood MarkEVP & Chief Operating Officer
|
SaleCommon Stock | 6,120 | $22.67 | $138,761.82 |
DisclosureSEC source: 0001193125-26-011885 · ownership.xml · nonDerivative · entry 2 Hollywood Mark · CIK 0002104446 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,913 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:11 UTC |
Hollywood MarkEVP & Chief Operating Officer
|
Exercise / conversionCommon Stock | 17,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-011885 · ownership.xml · nonDerivative · entry 1 Hollywood Mark · CIK 0002104446 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.